Confo Therapeutics
Confo Therapeutics discovers novel medicines targeting G-protein coupled receptors (GPCRs), focusing on Class B GPCRs for the treatment of chronic endocrine and metabolic diseases. Their proprietary platform, including ConfoBody® and ConfoChimer® technologies, enables the discovery of molecules targeting challenging GPCRs. The company is advancing a pipeline of large and small molecules.
Funding Round: Grant
Funding Amount: €1.6M
Date: 28-Mar-2024
Investors: VLAIO
Markets: Pharmaceuticals, Biotechnology, Drug Discovery
HQ: Ghent, Flanders, Belgium
Founded: 2015
Website: https://www.confotherapeutics.com/
LinkedIn: https://be.linkedin.com/company/confo-therapeutics
Crunchbase: https://www.crunchbase.com/organization/confo-therapeutics
Similar Startups
Schrödinger
Date: 18-Nov-2024
Markets: Pharmaceuticals, Biotechnology,...
HQ: New York, New York,...
Markets: Pharmaceuticals, Biotechnology,...
HQ: New York, New York,...
Leave a Comment
Comments
No comments yet.